Beam Therapeutics Inc.
BEAM
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$25.03
Price+1.38%
$0.34
1Y
Price
Market Cap
$2.540b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-1105.0%
EBITDA Margin-1162.4%
Net Profit Margin-891.8%
Free Cash Flow MarginRevenue
$55.701m
-12.3%
1y CAGR+141.5%
3y CAGR+110.5%
5y CAGREarnings
-$414.643m
-10.1%
1y CAGR-46.7%
3y CAGR-29.5%
5y CAGREPS
-$4.43
+3.3%
1y CAGR-34.9%
3y CAGR-19.1%
5y CAGRBook Value
$966.002m
$1.311b
Assets$345.079m
Liabilities$151.420m
DebtDebt to Assets
11.6%
-0.3x
Debt to EBITDAFree Cash Flow
-$352.360m
+1.1%
1y CAGR-228.6%
3y CAGR-152.3%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company